Clinical Trials Browser

OTHER × Triple Negative Breast Neoplasms × talazoparib × Clear all

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT05035745 2025-07-25

Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)

Phase 1/2 Recruiting

63 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04849364 2025-05-31

PERSEVERE

Phase 2 Terminated

52 enrolled 16 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03911973 2024-06-07

Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers

Phase 1/2 Active not recruiting

37 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04134884 2024-03-22

Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer

Phase 1 Completed

34 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04690855 2023-12-04

TARA

Phase 2 Terminated

1 enrolled 11 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02401347 2023-02-21

Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors

Phase 2 Completed

21 enrolled 12 charts

Breast

Triple Negative Breast Neoplasms

NCT05288127 2022-03-21

Efficacy of Talazoparib in Asian Metastatic Breast Cancer Patients With a Homologous Recombinant Deficiency (HRD) Signature

Phase 2 Unknown

55 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04755868 2021-02-16

Talazoparib Maintenance Therapy in Triple-negative Breast Cancer

Phase 2 Unknown

206 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Clinical Trials

I-SPY

Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)

PERSEVERE

Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers

Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer

TARA

Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors

Efficacy of Talazoparib in Asian Metastatic Breast Cancer Patients With a Homologous Recombinant Deficiency (HRD) Signature

Talazoparib Maintenance Therapy in Triple-negative Breast Cancer